MBD4 and neoplasm: In addition, evidence suggests that patients with MBD4 mutations respond to immune checkpoint blockade [126], likely due to the increased tumour mutational burden produced by the defect which causes wide-scale deamination of 5-methylcytosine (CpG to TpG).